Update information
Minor changes since publication
April 2026: Changes have been made to align this quality standard with the update to NICE's guideline on bladder cancer. Quality statement 6 on discussing treatment options for muscle-invasive urothelial bladder cancer has been updated to include the relevant technology appraisal guidance on durvalumab. Source guidance references and definitions have also been updated.
September 2025: Source guidance references were updated to align with changes to NICE's guideline on bladder cancer.